Clinical Trials Browser

Phase 2 × Completed × Urinary Bladder Neoplasms × Clear all

NCT07568444 2026-05-06

Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)

Phase 2 Completed

Adenocarcinoma, Urinary Bladder Neoplasms, Kidney Neoplasms, Prostatic Neoplasms, Testicular Neoplasms

NCT02690558 2026-03-20

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Phase 2 Completed

39 enrolled 16 charts

Urinary Bladder Neoplasms

NCT01616875 2026-03-06

Bristol Bladder Trial

Phase 2 Completed

28 enrolled 21 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04553939 2026-01-02

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02625961 2025-11-21

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Phase 2 Completed

Urinary Bladder Neoplasms

NCT03914794 2025-10-03

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Phase 2 Completed

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04383743 2025-09-18

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

Phase 2 Completed

17 enrolled 12 charts

Urinary Bladder Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02553642 2025-07-22

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

Phase 2 Completed

81 enrolled 12 charts

DermatologicGenitourinary

Urinary Bladder Neoplasms, Melanoma

NCT02015104 2025-07-01

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Phase 2 Completed

32 enrolled 16 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02662309 2025-03-10

ABACUS

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00627432 2025-02-18

Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Phase 2 Completed

Urinary Bladder Neoplasms

NCT01489813 2025-02-05

Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

Phase 2 Completed

36 enrolled 7 charts

Urinary Bladder Neoplasms

NCT01697306 2025-01-30

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

Phase 2 Completed

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04576286 2025-01-28

Holmium Versus Bipolar en Bloc Transurethral Resection of Urothelium Tumor of the Urinary Bladder

Phase 2 Completed

Urinary Bladder Neoplasms

NCT02662062 2025-01-27

PCR-MIB

Phase 2 Completed

28 enrolled 15 charts

Urinary Bladder Neoplasms

NCT03534804 2024-11-26

PemCab

Phase 2 Completed

37 enrolled 27 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00981656 2024-09-19

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

Phase 2 Completed

37 enrolled 19 charts

Urinary Bladder Neoplasms

NCT02177695 2024-09-19

COXEN

Phase 2 Completed

237 enrolled 20 charts

Urinary Bladder Neoplasms

NCT04593862 2024-09-19

BRAVE

Phase 2 Completed

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Motor Activity

NCT03219333 2024-08-27

EV-201

Phase 2 Completed

219 enrolled 32 charts 2 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Phase 2 Completed

47 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2 Completed

673 enrolled 22 charts

GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT03558087 2024-06-27

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Phase 2 Completed

76 enrolled 14 charts

Urinary Bladder Neoplasms

NCT03319745 2024-06-25

Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy

Phase 2 Completed

23 enrolled 10 charts

Urinary Bladder Neoplasms

NCT04525131 2024-06-18

Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors

Phase 2 Completed

12 enrolled 11 charts

Urinary Bladder Neoplasms

NCT02108652 2024-03-28

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)

Phase 2 Completed

310 enrolled 23 charts

Urinary Bladder Neoplasms

NCT02951767 2024-03-28

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)

Phase 2 Completed

119 enrolled 18 charts

Urinary Bladder Neoplasms

NCT04496219 2024-01-02

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

Phase 2 Completed

45 enrolled 16 charts

Urinary Bladder Neoplasms

NCT00002914 2023-06-22

Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00003129 2023-06-22

Chemotherapy in Treating Patients With Early-Stage Bladder Cancer

Phase 2 Completed

Urinary Bladder Neoplasms

NCT00005644 2023-06-22

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00053209 2023-06-22

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT01684098 2023-06-22

Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor

Phase 2 Completed

GastrointestinalGenitourinaryHead & Neck

Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Recurrence, Testicular Neoplasms

NCT04311580 2023-06-22

Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure

Phase 2 Completed

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT00004223 2023-06-18

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT03472274 2023-04-13

DUTRENEO

Phase 2 Completed

Urinary Bladder Neoplasms

NCT04209192 2023-04-04

Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB)

Phase 2 Completed

Urinary Bladder Neoplasms, Urinary Tract Infections

NCT03785925 2023-03-28

PIVOT-10

Phase 2 Completed

192 enrolled 16 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT02335424 2023-03-02

MK-3475-052

Phase 2 Completed

374 enrolled 37 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT02281383 2023-02-08

Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer

Phase 2 Completed

80 enrolled 9 charts

Urinary Bladder Neoplasms

NCT03058757 2023-01-31

The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation

Phase 2 Completed

Urinary Bladder Neoplasms

NCT03212651 2023-01-20

PANDORE

Phase 2 Completed

Urinary Bladder Neoplasms

NCT02581982 2023-01-10

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

Phase 2 Completed

27 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03617913 2023-01-06

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Phase 2 Completed

2 enrolled 8 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT00805129 2022-11-25

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Phase 2 Completed

46 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03980041 2022-11-25

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01688999 2022-10-18

Cabozantinib for Advanced Urothelial Cancer

Phase 2 Completed

69 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Urethral Neoplasms